Pharnext logo

Great News From HNF TRIAD Industry Partner — Pharnext

by | Aug 2, 2023 | 0 comments

Pharnext, a biopharmaceutical company, has announced new positive results from the ongoing open-label extension study of their drug PXT3003 in Charcot-Marie-Tooth Disease Type 1A (CMT1A), called the PLEO-CMT-FU trial. The trial has been conducted for a total of 6 years, and the data is consistent with a long-term treatment benefit of PXT3003 in patients with mild-to-moderate CMT1A. The results indicate that PXT3003 has a good safety profile and shows a long-term treatment effect on the Overall Neuropathy Limitation Scale (ONLS), which measures functional motor disability. A group of 117 patients with mild-to-moderate CMT1A are still receiving treatment with the high dose of PXT3003 in the trial.

Learn more on this topic

Related Blog Posts

The Key Role CMT Patients Play in Research

The Key Role CMT Patients Play in Research

Without your participation, researchers won’t have the essential patient information to develop drugs, gene therapies, and clinical trials for Charcot-Marie-Tooth and other Inherited Neuropathies. In addition, as GRIN grows, we gain greater insights from you as patients to help accelerate therapies for Charcot-Marie-Tooth (CMT) and Inherited Neuropathies.

Join the conversation

Leave a Comment

0 Comments

Submit a Comment

Your email address will not be published. Required fields are marked *

Newsletter

Join for notifications on events, campaigns, & news